UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 2, 2011
PLC Systems, Inc.
(Exact Name of Registrant as Specified in Charter)
Yukon Territory, Canada |
|
1-11388 |
|
04-3153858 |
(State or other Jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer |
PLC Systems, Inc. |
|
02038 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: 508-541-8800
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective May 2, 2011, James G. Thomasch, Chief Financial Officer of the Registrant, resigned all of his positions as an officer of the Company.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PLC SYSTEMS, INC. | |
|
| |
|
| |
Date: May 5, 2011 |
By: |
/s/ MARK R. TAUSCHER |
|
|
Mark R. Tauscher, President and |
|
|
Chief Executive Officer |
Exhibit 99.1
FOR IMMEDIATE RELEASE |
|
Contact: Mary T. Conway |
|
|
Conway Communications |
|
|
617-244-9682 |
|
|
marytconway@comcast.net |
PLC Systems Chief Financial Officer to Leave Company
To Become CEO of Clinquest
FRANKLIN, Mass., April 22, 2011 --- PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, today announced that its Chief Financial Officer, James G. Thomasch, will leave the company effective May 2, 2011, to become Chief Executive Officer at Clinquest, Inc., a privately-held company. PLCs Controller, Karen Raus, will fulfill the financial reporting duties previously handled by Mr. Thomasch upon his departure. Ms. Raus has served as PLCs Corporate Controller since August 1996 and is a certified public accountant.
Said Mark Tauscher, President and CEO, Jim has been a talented and resourceful partner in our long-standing effort to remake PLC Systems into a new company around our RenalGuard® technology. All of us so appreciate his diligence and acumen as weve faced a variety of challenges over the years. We understand Jims desire to step into an exciting new leadership role for him at this time in his career, and we wish him all the best.
About PLC Systems Inc.
PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Massachusetts, PLC today focuses on its newest product, RenalGuard, which is approved for sale in the EU as a general fluid balancing device. Additional company information can be found at www.plcmed.com.
This press release contains forward-looking statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as believes, anticipates, plans, expects, will and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the current clinical trials in Italy and the planned future U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if these clinical trials are completed, they may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the Forward Looking Statements section of our Annual Report on Form 10-K for the year ended December 31, 2010, a copy of which is filed with the SEC.
PLC Systems, PLC Medical Systems, PLC, RenalGuard and RenalGuard System are trademarks of PLC Systems Inc.